List of Excipients in Branded Drug CAREONE IBUPROFEN PM

« Back to Dashboard

Generic Drugs Containing CAREONE IBUPROFEN PM

Company	Ingredient	NDC	Excipient
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	CELLULOSE, MICROCRYSTALLINE
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	CROSCARMELLOSE SODIUM
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	GLYCERYL DIBEHENATE
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	LACTOSE MONOHYDRATE
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	MAGNESIUM STEARATE
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	POLYETHYLENE GLYCOL
American Sales Company	diphenhydramine citrate, ibuprofen	41520-413	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in CAREONE IBUPROFEN PM?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	GLYCERYL DIBEHENATE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	POLYVINYL ALCOHOL

Last updated: October 9, 2026

ecutive summary: CareOne Ibuprofen PM is an OTC nighttime analgesic combining ibuprofen 200 mg with diphenhydramine citrate equivalent to diphenhydramine HCl 25 mg per tablet. Its commercial value depends less on molecule exclusivity than on low-cost tableting, stable moisture control, acceptable swallowability, packaging compliance, and retailer supply economics. The strongest excipient opportunities are fast-disintegrating tablets, smaller-dose-unit formats, film-coating improvements, tamper-evident packaging, and differentiated nighttime delivery systems that remain within FDA OTC monograph conditions.

CareOne Ibuprofen PM Excipient Strategy and Commercial Opportunities

CareOne Ibuprofen PM competes in a mature OTC category dominated by private-label products and national brands such as Advil PM and Motrin PM. The formulation is technically straightforward but commercially sensitive. Small changes in excipient cost, tablet size, coating performance, packaging yield, or dissolution can affect retailer margins and manufacturing reliability.

The core formulation challenge is combining a poorly water-soluble NSAID with a sedating antihistamine in a stable, rapidly disintegrating tablet. Ibuprofen generally requires particle engineering, wetting support, or granulation control to produce consistent dissolution. Diphenhydramine salts are more water-soluble but can contribute to blend segregation, taste, hygroscopicity, and tablet-weight variability.

What is CareOne Ibuprofen PM and how is it regulated?

CareOne Ibuprofen PM is an OTC combination product marketed for temporary relief of minor aches and pains with nighttime sleep-aid positioning. The typical active-ingredient profile is:

Component	Typical strength per tablet	Regulatory role
Ibuprofen	200 mg	Analgesic and antipyretic NSAID
Diphenhydramine citrate or equivalent salt	Equivalent to 25 mg diphenhydramine	Nighttime sleep-aid ingredient

Ibuprofen products are regulated under the FDA OTC internal analgesic framework in 21 C.F.R. Part 343. Diphenhydramine sleep-aid products are addressed under 21 C.F.R. Part 338. FDA labeling must state the active ingredients, purposes, warnings, directions, and applicable contraindications. [1,2]

CareOne is a private-label retail brand. The product may be manufactured by a contract manufacturer rather than by the retailer itself. The exact excipient composition, manufacturing site, and tablet tooling can vary by supplier, product revision, or market.

What are the likely inactive ingredients?

Common excipient classes for an ibuprofen-diphenhydramine tablet include:

• Microcrystalline cellulose as a filler and compression aid
• Croscarmellose sodium or sodium starch glycolate as a superdisintegrant
• Povidone or copovidone as a binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Hypromellose, polyethylene glycol, and titanium dioxide in a film coat
• Colorants for product identification
• Sodium lauryl sulfate or another wetting agent in selected formulations

The exact CareOne composition should be taken from the current package insert, Drug Facts label, or DailyMed record for the applicable National Drug Code. Inactive ingredients can change without changing the active-ingredient claim, provided the revised product remains compliant with applicable quality and regulatory requirements.

What excipient strategy best fits CareOne Ibuprofen PM?

The preferred strategy is a cost-controlled immediate-release tablet with robust content uniformity, rapid disintegration, low friability, and a thin protective film coat.

Immediate-release core

A direct-compression formulation offers the lowest process complexity, but ibuprofen’s flow and compaction properties can be difficult. A practical formulation platform may use:

Formulation function	Candidate excipients	Commercial rationale
Dilution and compression	Microcrystalline cellulose, dibasic calcium phosphate, spray-dried lactose	Controls tablet hardness and cost
Disintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid release after ingestion
Binding	Povidone, copovidone, pregelatinized starch	Improves granule and tablet integrity
Wetting	Sodium lauryl sulfate or poloxamer	May improve ibuprofen wetting and dissolution
Flow control	Colloidal silicon dioxide	Reduces weight variation and improves hopper flow
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling wear
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance, handling, identification, and swallowability

The formulation should avoid excessive lubricant concentration or over-lubrication time. These conditions can reduce tablet tensile strength and delay dissolution, particularly in a high-drug-load formulation.

Granulation versus direct compression

Wet granulation can improve ibuprofen flow and content uniformity, but it adds drying, moisture, cycle-time, and stability burdens. It is more attractive where the active ingredients have different particle-size distributions or where direct compression produces unacceptable weight variation.

Dry granulation can reduce moisture exposure and may be suitable for a high-throughput product. It can also create dense granules that slow disintegration if the formulation lacks an effective superdisintegrant system.

Direct compression is commercially attractive when the supplier can obtain consistent, engineered ibuprofen and diphenhydramine raw materials. The best process should be selected through comparative development rather than by excipient cost alone.

What formulation patents could protect an ibuprofen PM product?

A conventional ibuprofen-diphenhydramine tablet has limited patent leverage because the active ingredients, basic dosage strengths, and therapeutic use are longstanding. A composition that uses ordinary fillers, binders, disintegrants, lubricants, and film coats is unlikely to support a strong, broad patent position without an unexpected technical result.

Potentially protectable subject matter includes:

1. A specific particle-size or polymorph combination that improves dissolution or stability.
2. A low-dose-unit tablet that reduces tablet size while maintaining content uniformity.
3. A taste-masked or orally disintegrating formulation.
4. A modified-release system that separates analgesic and sedative release profiles.
5. A moisture-protective formulation with demonstrated shelf-life advantages.
6. A co-processed excipient system that improves compression and dissolution.
7. A manufacturing process that produces a defined solid-state form or impurity profile.

Any patent claim would need evidence showing that the formulation performs better than routine combinations of known excipients. Useful comparative data would include dissolution profiles, tablet hardness, friability, content uniformity, accelerated stability, impurity growth, and pharmacokinetic performance where relevant.

How strong is the patent estate for CareOne Ibuprofen PM?

The likely patent estate is weak relative to prescription products. The commercial product is an OTC private-label combination using established active ingredients. Exclusivity is more likely to arise from:

• Supplier-specific manufacturing know-how
• Qualification of low-cost raw-material sources
• Process validation
• Packaging and artwork controls
• Retail distribution agreements
• Quality-system execution
• Short-term procurement advantages

These assets can create commercial friction for competitors but generally do not prevent a compliant competitor from launching an equivalent OTC product.

What is the Orange Book status of CareOne Ibuprofen PM?

The FDA Orange Book is primarily relevant to approved prescription and certain other NDA products. A standard OTC monograph product is not normally protected through Orange Book-listed patents in the same manner as an NDA product.

A conventional CareOne Ibuprofen PM product should therefore not be analyzed as an Orange Book exclusivity asset. The relevant regulatory questions are whether:

• The active ingredients and strengths comply with applicable OTC monographs.
• The labeling follows FDA requirements.
• The product is manufactured under current good manufacturing practice.
• The drug listing and facility information are properly maintained.
• Any formulation or manufacturing patent is enforceable independently of Orange Book listing.

When does CareOne Ibuprofen PM lose exclusivity?

CareOne Ibuprofen PM does not have a meaningful molecule-level exclusivity period. Ibuprofen and diphenhydramine are long-established OTC ingredients. A competing manufacturer can generally market a comparable product if it satisfies FDA OTC requirements, labeling rules, manufacturing controls, and applicable state and federal obligations.

The practical exclusivity timeline is therefore:

Commercial asset	Expected duration
Active-ingredient exclusivity	None of practical significance
OTC monograph positioning	Available to qualifying competitors
Retailer private-label placement	Contract-dependent
Supplier qualification advantage	Can persist while pricing and quality remain superior
Formulation patent	Depends on claim scope, validity, and expiration
Brand recognition	Can persist through retailer distribution and shelf placement

What generic entry risks exist for CareOne Ibuprofen PM?

Generic and private-label entry risk is high. The principal entry routes are:

• A conventional tablet with the same active ingredients
• A lower-cost capsule or caplet
• A competing nighttime pain reliever
• A store-brand product sourced from another contract manufacturer
• A national-brand promotion that compresses private-label price gaps
• A multi-pack or club-store format with a lower unit cost

Regulatory entry is simpler than for a prescription drug because an applicant can rely on established OTC monograph conditions rather than demonstrate a new clinical benefit. Product similarity remains important, but the central competitive variables are price, availability, package count, tablet appearance, and retailer economics.

What excipient innovations can create commercial differentiation?

Smaller tablets and caplets

A 200 mg ibuprofen dose consumes substantial tablet volume. High-density fillers such as dibasic calcium phosphate, optimized granulation, and low-level multifunctional excipients can reduce tablet size. A smaller unit may improve swallowability and reduce packaging volume.

The main risks are slower disintegration, higher compression force, and increased sensitivity to lubricant level. A smaller tablet must retain rapid release and acceptable mechanical strength.

Fast-disintegrating tablets

Crospovidone and croscarmellose sodium can support rapid breakup without requiring an orally disintegrating-tablet claim. This approach can improve patient perception and may reduce variability caused by prolonged tablet dispersion.

An orally disintegrating version could create a stronger product distinction, but ibuprofen’s taste and dose load make taste masking difficult. Sweeteners, flavors, ion-exchange resins, coated particles, and specialized granules would increase cost and regulatory complexity.

Film-coat optimization

A thin, durable film coat can reduce dusting, improve swallowability, and distinguish the product visually. The coating must not materially delay release or create unacceptable tablet-to-tablet color variation.

Colorants also affect supply-chain resilience. A dye-free or iron-oxide-based color system could reduce certain consumer concerns and simplify procurement, but it may require new artwork and retailer approval.

Moisture protection

Ibuprofen-diphenhydramine tablets may benefit from high-barrier bottles, induction seals, desiccants, or blister packaging. Moisture control can reduce impurity formation, tablet softening, coating defects, and dissolution drift.

Blister packaging provides unit-dose protection and tamper evidence but often has higher packaging cost than bottles. It may be attractive for travel packs, pharmacy channels, or premium private-label variants.

Excipient substitution and supply resilience

A dual-source strategy should qualify alternatives for:

• Superdisintegrants
• Microcrystalline cellulose
• Magnesium stearate
• Film-coating systems
• Pigments and colorants
• Bottle and closure components

Substitutions must be evaluated for powder flow, tablet compression, dissolution, stability, and appearance. Excipient changes can create post-approval documentation and validation requirements even when the active-ingredient label is unchanged.

What manufacturing and intellectual-property barriers matter most?

The most important barriers are operational rather than patent-based.

Content uniformity

Ibuprofen represents most of the tablet mass, while diphenhydramine is present at a lower active level. Segregation can produce potency variation if particle-size distributions, density, or electrostatic behavior differ significantly.

Dissolution

Ibuprofen’s poor aqueous solubility makes dissolution a key critical quality attribute. Wetting agents, particle-size control, granulation, and disintegrant placement can have greater commercial value than a minor reduction in excipient cost.

Stability

The development program should monitor assay, related substances, water content, tablet hardness, friability, appearance, and dissolution under long-term and accelerated conditions. Packaging selection should be based on stability data rather than standard bottle practice.

Tooling and process transfer

High-speed compression can generate capping, sticking, picking, and weight variation. Tooling geometry, precompression, dwell time, lubrication, and ejection force should be controlled during site transfer.

Supplier qualification

A private-label product may depend on a narrow group of qualified suppliers. A second source for the active pharmaceutical ingredients and critical excipients can protect continuity but may alter tablet performance.

How does CareOne Ibuprofen PM compare with competing nighttime pain relievers?

Product category	Active ingredients	Main differentiation	Competitive risk
CareOne Ibuprofen PM	Ibuprofen plus diphenhydramine	Retailer private label and price	High
Advil PM-type product	Ibuprofen plus diphenhydramine	National brand recognition	High
Acetaminophen-diphenhydramine product	Acetaminophen plus diphenhydramine	Alternative analgesic profile	High
Doxylamine sleep-aid combination	Analgesic plus doxylamine in some products	Different sedating antihistamine	Moderate
Plain ibuprofen	Ibuprofen only	No sedating ingredient	Substitution risk
Plain diphenhydramine	Diphenhydramine only	Sleep-aid positioning	Substitution risk

The principal medical and regulatory differentiation is the analgesic ingredient. Ibuprofen may be preferred for inflammatory pain, while acetaminophen-based products avoid NSAID-specific warnings but carry different safety considerations. Labeling must present the risks clearly and avoid implying superior efficacy without supporting evidence.

What are the licensing and commercial opportunities?

Licensing opportunities are more likely to involve formulation technology, manufacturing capacity, or packaging than the product name itself.

Excipient and formulation licensing

Potential targets include:

• Co-processed direct-compression excipients
• Low-moisture granulation systems
• Rapid-disintegration platforms
• Taste-masking technology
• High-barrier unit-dose packaging
• Continuous manufacturing systems
• Engineered ibuprofen particles

A license is commercially justified only if it improves a measurable metric such as tablet size, dissolution, yield, stability, packaging cost, or manufacturing throughput.

Contract-manufacturing opportunities

A manufacturer can compete for private-label supply by offering:

• Dual-site manufacturing
• Lower minimum order quantities
• Flexible package counts
• Faster retailer replenishment
• Validated alternate excipient sources
• Strong OTC quality documentation
• Competitive bottle, blister, and carton options

For CareOne, the value proposition is likely to be supply reliability and landed cost rather than a proprietary active ingredient.

Premium private-label variants

Possible extensions include:

• Smaller caplets
• Dye-free tablets
• Unit-dose blister packs
• Travel-size packages
• Higher-barrier packaging
• Rapid-disintegration tablets
• Larger value packs
• Combination packs with non-drug sleep or wellness products, subject to regulatory controls

Any variant using new claims, altered release characteristics, or a new dosage form requires separate regulatory and quality assessment.

What revenue exposure does the formulation strategy create?

Brand-level CareOne revenue is not generally disclosed as a standalone public metric. Commercial exposure is better assessed through category economics:

1. Retail shelf placement and planogram access.
2. Unit cost compared with other private-label suppliers.
3. Gross margin after packaging and retailer fees.
4. Product availability during seasonal demand.
5. Recall and quality-event risk.
6. Conversion potential from branded nighttime analgesics.
7. Package-size mix and repeat purchase.

For a mature OTC product, a one-cent reduction in fully loaded unit cost can materially affect annual contribution when multiplied across large-volume retail distribution. The economic value of a new excipient should therefore be measured against annual tablet volume, not only laboratory performance.

What is the likely generic launch scenario?

A competitor could launch a conventional ibuprofen-diphenhydramine tablet without waiting for CareOne-specific patent expiration, provided the product meets FDA requirements. The most likely launch sequence is:

1. A low-cost equivalent tablet using standard excipients.
2. A different tablet color, shape, or package count.
3. Retailer-specific private-label placement.
4. Price promotion or multi-pack discounting.
5. Migration to an alternate manufacturer if supply economics improve.

A differentiated formulation can delay substitution only if it has a defensible performance or cost advantage. A conventional excipient combination alone is unlikely to prevent entry.

Key takeaways

• CareOne Ibuprofen PM is an OTC ibuprofen-diphenhydramine combination with limited molecule-level exclusivity.
• The strongest commercial strategy is a stable, fast-disintegrating, low-cost immediate-release tablet.
• Excipient value is concentrated in dissolution, flow, compression, moisture protection, and supply continuity.
• Conventional formulation patents are likely to be narrow and vulnerable unless supported by comparative technical data.
• Orange Book exclusivity is generally not the central protection mechanism for a monograph OTC product.
• Generic and private-label entry risk is high.
• The best licensing opportunities involve excipient platforms, packaging, process technology, and contract manufacturing.
• Revenue protection depends more on retailer economics, manufacturing reliability, and quality performance than on patent enforcement.

FAQs about CareOne Ibuprofen PM excipient and commercial strategy

Can CareOne Ibuprofen PM use the same excipients as Advil PM?

Yes. Excipients are not exclusive merely because they appear in a branded product. A competing formulation must independently meet quality, stability, labeling, and manufacturing requirements.

Is ibuprofen the main dissolution problem in the formulation?

Usually. Ibuprofen has limited aqueous solubility, so particle size, wetting, granulation, disintegrant selection, and lubricant control can materially affect dissolution.

Can an excipient formulation patent block a generic nighttime pain reliever?

Only if the generic product falls within valid, enforceable patent claims. Broad claims covering ordinary tablet excipients are difficult to sustain without unexpected performance data.

Would a blister pack create meaningful product differentiation?

It can improve unit-dose protection, tamper evidence, portability, and moisture control. Its commercial value depends on whether the retailer and consumer accept the higher packaging cost.

Is a diphenhydramine-based nighttime product interchangeable with a doxylamine-based product?

No. The active sedating antihistamine, labeling, safety profile, dosing instructions, and regulatory basis differ. A doxylamine product is a competitive substitute but not the same formulation or regulatory product.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 338: Sleep aid drug products for over-the-counter human use. Electronic Code of Federal Regulations.

3. U.S. Food and Drug Administration. (2024). FDA OTC monograph drugs. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). Inactive ingredient database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211. Electronic Code of Federal Regulations.